Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
A few years ago Pascal Soriot claimed to be the sector’s worst paid CEO, but share price-linked bonuses have bumped up his remuneration, and shareholders have now approved a new plan.
Novavax’s timelines are slipping once again, giving frontrunners Pfizer and Moderna the chance to consolidate their dominance in the market.
Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.
After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.
The UK’s purchase of 60 million extra Pfizer/BioNTech COVID vaccine doses, plus bets on Novavax and Valneva and others gives it a buffer against new variants – so when will it pledge to donate to more needy nations?
While White House support for an intellectual property waiver has been cheered by access campaigners, Moderna said it won’t help solve the pandemic’s big vaccine production challenges any time soon.